Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stefano Annunziato, Julian R. de Ruiter, Linda Henneman, Chiara S. Brambillasca, Catrin Lutz, François Vaillant, Federica Ferrante, Anne Paulien Drenth, Eline van der Burg, Bjørn Siteur, Bas van Gerwen, Roebi de Bruijn, Martine H. van Miltenburg, Ivo J. Huijbers, Marieke van de Ven, Jane E. Visvader, Geoffrey J. Lindeman, Lodewyk F. A. Wessels, Jos Jonkers
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/d9ac65cbd345403caaf37726c9a7d740
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbation of candidate driver genes, validating drivers Myc, Met, Pten and Rb1, and identifying MCL1 as a collaborating driver whose targeting can impact efficacy of PARP inhibition.

Ejemplares similares